New Trial to Test MRD-Guided Escalation in Advanced Melanoma
A newly announced trial will evaluate whether measurable residual disease testing can trigger earlier treatment escalation in advanced melanoma, potentially reshaping surveillance.
Topic
Clinical Trial
Topic
Clinical Trial
First Patient Treated in Trial Targeting Immunotherapy Resistance
The Institute of Cancer Research has treated the first patient in a new clinical trial targeting immunotherapy resistance in lung…
MRD-Guided Melanoma Trial Enrolls First Patients With Signatera
First patients enrolled in NCT07504796: Signatera-positive melanoma patients randomized at week six to ipilimumab escalation or c…
IDO1 Inhibitor Fails to Amplify T-Cell Response to Melanoma Vaccine
A clinical trial reports that combining an IDO1 inhibitor with a melanoma vaccine did not increase tumor-fighting T cells, underm…
Upadacitinib Sustains Repigmentation at Week 76 in Non-Segmental Vitiligo
Long-term extension data show repigmentation maintained through 76 weeks in non-segmental vitiligo patients receiving oral upadac…
Natera Launches Randomized Signatera-Guided Interventional Melanoma Study
Natera will run a randomized interventional melanoma study using its tumor-informed Signatera ctDNA assay to guide treatment, shi…
Zasocitinib Beats Deucravacitinib Head-to-Head in Phase 3 Psoriasis
In the Phase 3 LATITUDE Atlas head-to-head trial, zasocitinib achieved PASI-100 in 36.5% of patients at Week 16 versus 13.9% for…
Lilly's Ebglyss Meets Endpoints in Phase 3b Hand and Foot AD Trial
Ebglyss met primary and secondary endpoints at 16 weeks in Phase 3b ADtouch, improving clearance, itch and pain in moderate-to-se…
Investigational Drug Shows Early Promise in NRAS-Mutant Melanoma
University of Utah Health reports an investigational drug shows promise in NRAS-driven melanoma, a subtype lacking targeted optio…